TY - JOUR
T1 - Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary
AU - Talukdar, Shobhana
AU - Kumar, Sunesh
AU - Bhatla, Neerja
AU - Mathur, S.
AU - Thulkar, S.
AU - Kumar, Lalit
PY - 2014/1
Y1 - 2014/1
N2 - Objective In order to preserve fertility, we attempted neo-adjuvant chemotherapy (NACT) in patients of malignant ovarian germ cell tumor (MOGCT) with advance and bulky disease. Patients and methods Between January 1988 and December 2009, 23 patients received NACT. Patient's median age was 19 years, ranging from 14 to 28 years. FIGO stages III - 20 and IV - 3. Histology subtypes were: dysgerminoma, n = 14, mixed GCT, n = 6 and 3 had endodermal sinus tumor. Patients were planned for four cycles of BEP (bleomycin, etoposide and cisplatin) chemotherapy followed by fertility sparing surgery (unilateral salpingo-oophorectomy + omentectomy ± lymphadenectomy). Results Following NACT - 21 patients responded; complete (CR) - 16 and partial response (PR) - 5. One patient progressed and another was lost to follow-up after 2 cycles. 18 of 21 responders underwent surgery; 13/18 had pathological CR, 5/18 had residual disease and achieved CR following 2 more cycles of BEP. 3 patients refused for surgery; 2 relapsed at 9 and 12 months, and achieved second CR following salvage chemotherapy and surgery, third patient continues to be disease-free. Currently, 21 of 23 patients are alive and disease-free at a median follow-up of 74 months. 18/21 patients have resumed menstruation and 10 eligible patients have delivered 13 full term healthy babies. These results are comparable to patients with advanced disease (n = 43) treated with standard approach (initial surgery and adjuvant chemotherapy) during the same period. Conclusion NACT followed by fertility sparing surgery could be a reasonable option for patients of advanced MOGCT, not suitable for optimal cyto-reduction.
AB - Objective In order to preserve fertility, we attempted neo-adjuvant chemotherapy (NACT) in patients of malignant ovarian germ cell tumor (MOGCT) with advance and bulky disease. Patients and methods Between January 1988 and December 2009, 23 patients received NACT. Patient's median age was 19 years, ranging from 14 to 28 years. FIGO stages III - 20 and IV - 3. Histology subtypes were: dysgerminoma, n = 14, mixed GCT, n = 6 and 3 had endodermal sinus tumor. Patients were planned for four cycles of BEP (bleomycin, etoposide and cisplatin) chemotherapy followed by fertility sparing surgery (unilateral salpingo-oophorectomy + omentectomy ± lymphadenectomy). Results Following NACT - 21 patients responded; complete (CR) - 16 and partial response (PR) - 5. One patient progressed and another was lost to follow-up after 2 cycles. 18 of 21 responders underwent surgery; 13/18 had pathological CR, 5/18 had residual disease and achieved CR following 2 more cycles of BEP. 3 patients refused for surgery; 2 relapsed at 9 and 12 months, and achieved second CR following salvage chemotherapy and surgery, third patient continues to be disease-free. Currently, 21 of 23 patients are alive and disease-free at a median follow-up of 74 months. 18/21 patients have resumed menstruation and 10 eligible patients have delivered 13 full term healthy babies. These results are comparable to patients with advanced disease (n = 43) treated with standard approach (initial surgery and adjuvant chemotherapy) during the same period. Conclusion NACT followed by fertility sparing surgery could be a reasonable option for patients of advanced MOGCT, not suitable for optimal cyto-reduction.
KW - Bleomycin, etoposide, cisplatin
KW - Complete response
KW - Fertility
KW - Malignant ovarian germ cell tumors
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=84892809298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892809298&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2013.10.009
DO - 10.1016/j.ygyno.2013.10.009
M3 - Article
C2 - 24145115
AN - SCOPUS:84892809298
SN - 0090-8258
VL - 132
SP - 28
EP - 32
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -